Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study

Tristan Ferry,Anne Conrad,Eric Senneville,Sandrine Roux,Celine Dupieux-Chabert,Aurelien Dinh,Sebastien Lustig,Sylvain Goutelle,Thomas Briot,Truong-Thanh Pham,Florent Valour

OPEN FORUM INFECTIOUS DISEASES（2021）

引用 5|浏览1

暂无评分

摘要

A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.

查看译文

关键词

bone and joint infection, linezolid, periprosthetic joint infection, suppressive antimicrobial therapy, tedizolid

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要